Literature DB >> 21212469

Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves' disease.

S Merrill1, J Horowitz, A C Traino, S R Chipkin, C V Hollot, Y Chait.   

Abstract

Calculation of the therapeutic activity of radioiodine (131)I for individualized dosimetry in the treatment of Graves' disease requires an accurate estimate of the thyroid absorbed radiation dose based on a tracer activity administration of (131)I. Common approaches (Marinelli-Quimby formula, MIRD algorithm) use, respectively, the effective half-life of radioiodine in the thyroid and the time-integrated activity. Many physicians perform one, two, or at most three tracer dose activity measurements at various times and calculate the required therapeutic activity by ad hoc methods. In this paper, we study the accuracy of estimates of four 'target variables': time-integrated activity coefficient, time of maximum activity, maximum activity, and effective half-life in the gland. Clinical data from 41 patients who underwent (131)I therapy for Graves' disease at the University Hospital in Pisa, Italy, are used for analysis. The radioiodine kinetics are described using a nonlinear mixed-effects model. The distributions of the target variables in the patient population are characterized. Using minimum root mean squared error as the criterion, optimal 1-, 2-, and 3-point sampling schedules are determined for estimation of the target variables, and probabilistic bounds are given for the errors under the optimal times. An algorithm is developed for computing the optimal 1-, 2-, and 3-point sampling schedules for the target variables. This algorithm is implemented in a freely available software tool. Taking into consideration (131)I effective half-life in the thyroid and measurement noise, the optimal 1-point time for time-integrated activity coefficient is a measurement 1 week following the tracer dose. Additional measurements give only a slight improvement in accuracy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212469     DOI: 10.1088/0031-9155/56/3/003

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  6 in total

1.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases.

Authors:  Heribert Hänscheid; Cristina Canzi; Wolfgang Eschner; Glenn Flux; Markus Luster; Lidia Strigari; Michael Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-11       Impact factor: 9.236

2.  Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach.

Authors:  Valentina Topić Vučenović; Zvezdana Rajkovača; Dijana Jelić; Dragi Stanimirović; Goran Vuleta; Branislava Miljković; Katarina Vučićević
Journal:  Eur J Clin Pharmacol       Date:  2018-05-13       Impact factor: 2.953

3.  Models for the red blood cell lifespan.

Authors:  Rajiv P Shrestha; Joseph Horowitz; Christopher V Hollot; Michael J Germain; John A Widness; Donald M Mock; Peter Veng-Pedersen; Yossi Chait
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-04-02       Impact factor: 2.745

4.  A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE.

Authors:  Theresa P Devasia; Yuni K Dewaraja; Kirk A Frey; Ka Kit Wong; Matthew J Schipper
Journal:  J Nucl Med       Date:  2020-12-18       Impact factor: 10.057

5.  Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry.

Authors:  Andreas Rinscheid; Peter Kletting; Matthias Eiber; Ambros J Beer; Gerhard Glatting
Journal:  EJNMMI Phys       Date:  2020-06-17

6.  Gender differences in estimating I-131 thyroid uptake from Tc-99m thyroid uptake for benign thyroid disease.

Authors:  Amna Al-Jabri; Jennie Cooke; Seán Cournane; Marie-Louise Healy
Journal:  Br J Radiol       Date:  2020-12-11       Impact factor: 3.039

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.